Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives
Our development and usage of engineered nanomaterials has grown exponentially despite concerns about their unfavourable cardiorespiratory consequence, one that parallels ambient ultrafine particle exposure from vehicle emissions. Most research in the field has so far focused on airway inflammation i...
Saved in:
Main Authors: | , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2018
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/89669 http://hdl.handle.net/10220/47125 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-89669 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-896692020-11-01T05:31:27Z Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives Nur A’tikah Binte Mohamed Ali Mustafa Hussain Kathawala Poh, Tuang Yeow Mac Aogáin, Micheál Setyawati, Magdiel Inggrid Ng, Kee Woei Chotirmall, Sanjay Haresh School of Materials Science & Engineering Lee Kong Chian School of Medicine (LKCMedicine) Translational Respiratory Research Laboratory Nanotoxicology DRNTU::Science::Medicine Nanoparticle Our development and usage of engineered nanomaterials has grown exponentially despite concerns about their unfavourable cardiorespiratory consequence, one that parallels ambient ultrafine particle exposure from vehicle emissions. Most research in the field has so far focused on airway inflammation in response to nanoparticle inhalation, however, little is known about nanoparticle-microbiome interaction in the human airway and the environment. Emerging evidence illustrates that the airway, even in its healthy state, is not sterile. The resident human airway microbiome is further altered in chronic inflammatory respiratory disease however little is known about the impact of nanoparticle inhalation on this airway microbiome. The composition of the airway microbiome, which is involved in the development and progression of respiratory disease is dynamic, adding further complexity to understanding microbiota-host interaction in the lung, particularly in the context of nanoparticle exposure. This article reviews the size-dependent properties of nanomaterials, their body deposition after inhalation and factors that influence their fate. We evaluate what is currently known about nanoparticle-microbiome interactions in the human airway and summarise the known clinical, immunological and toxicological consequences of this relationship. While associations between inhaled ambient ultrafine particles and host immune-inflammatory response are known, the airway and environmental microbiomes likely act as intermediaries and facilitate individual susceptibility to inhaled nanoparticles and toxicants. Characterising the precise interaction between the environment and airway microbiomes, inhaled nanoparticles and the host immune system is therefore critical and will provide insight into mechanisms promoting nanoparticle induced airway damage. MOE (Min. of Education, S’pore) NMRC (Natl Medical Research Council, S’pore) MOH (Min. of Health, S’pore) Published version 2018-12-20T06:52:33Z 2019-12-06T17:30:48Z 2018-12-20T06:52:33Z 2019-12-06T17:30:48Z 2018 Journal Article Poh, T. Y., Nur A’tikah Binte Mohamed Ali., Mac Aogáin, M., Mustafa Hussain Kathawala., Setyawati, M. I., Ng, K. W., & Chotirmall, S. H. (2018). Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives. Particle and Fibre Toxicology, 15(1), 46-. doi: 10.1186/s12989-018-0282-0 https://hdl.handle.net/10356/89669 http://hdl.handle.net/10220/47125 10.1186/s12989-018-0282-0 en Particle and Fibre Toxicology © 2018 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. 16 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Nanotoxicology DRNTU::Science::Medicine Nanoparticle |
spellingShingle |
Nanotoxicology DRNTU::Science::Medicine Nanoparticle Nur A’tikah Binte Mohamed Ali Mustafa Hussain Kathawala Poh, Tuang Yeow Mac Aogáin, Micheál Setyawati, Magdiel Inggrid Ng, Kee Woei Chotirmall, Sanjay Haresh Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
description |
Our development and usage of engineered nanomaterials has grown exponentially despite concerns about their unfavourable cardiorespiratory consequence, one that parallels ambient ultrafine particle exposure from vehicle emissions. Most research in the field has so far focused on airway inflammation in response to nanoparticle inhalation, however, little is known about nanoparticle-microbiome interaction in the human airway and the environment. Emerging evidence illustrates that the airway, even in its healthy state, is not sterile. The resident human airway microbiome is further altered in chronic inflammatory respiratory disease however little is known about the impact of nanoparticle inhalation on this airway microbiome. The composition of the airway microbiome, which is involved in the development and progression of respiratory disease is dynamic, adding further complexity to understanding microbiota-host interaction in the lung, particularly in the context of nanoparticle exposure. This article reviews the size-dependent properties of nanomaterials, their body deposition after inhalation and factors that influence their fate. We evaluate what is currently known about nanoparticle-microbiome interactions in the human airway and summarise the known clinical, immunological and toxicological consequences of this relationship. While associations between inhaled ambient ultrafine particles and host immune-inflammatory response are known, the airway and environmental microbiomes likely act as intermediaries and facilitate individual susceptibility to inhaled nanoparticles and toxicants. Characterising the precise interaction between the environment and airway microbiomes, inhaled nanoparticles and the host immune system is therefore critical and will provide insight into mechanisms promoting nanoparticle induced airway damage. |
author2 |
School of Materials Science & Engineering |
author_facet |
School of Materials Science & Engineering Nur A’tikah Binte Mohamed Ali Mustafa Hussain Kathawala Poh, Tuang Yeow Mac Aogáin, Micheál Setyawati, Magdiel Inggrid Ng, Kee Woei Chotirmall, Sanjay Haresh |
format |
Article |
author |
Nur A’tikah Binte Mohamed Ali Mustafa Hussain Kathawala Poh, Tuang Yeow Mac Aogáin, Micheál Setyawati, Magdiel Inggrid Ng, Kee Woei Chotirmall, Sanjay Haresh |
author_sort |
Nur A’tikah Binte Mohamed Ali |
title |
Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
title_short |
Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
title_full |
Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
title_fullStr |
Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
title_full_unstemmed |
Inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
title_sort |
inhaled nanomaterials and the respiratory microbiome : clinical, immunological and toxicological perspectives |
publishDate |
2018 |
url |
https://hdl.handle.net/10356/89669 http://hdl.handle.net/10220/47125 |
_version_ |
1683494520141905920 |